We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals

518 hedge funds and large institutions have $16.1B invested in BioMarin Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 190 increasing their positions, 191 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more call options, than puts

Call options by funds: $139M | Put options by funds: $87.5M

27% more funds holding in top 10

Funds holding in top 10: 11 → 14 (+3)

24% more capital inflows, than outflows

Capital inflows: $1.42B | Capital outflows: $1.15B

1.25% more ownership

Funds ownership: 95.19% → 96.43% (+1.2%)

1% less repeat investments, than reductions

Existing positions increased: 190 | Existing positions reduced: 191

7% less funds holding

Funds holding: 555 → 518 (-37)

53% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 75

Holders
518
Holders Change
-37
Holders Change %
-6.67%
% of All Funds
8.2%
Holding in Top 10
14
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+27.27%
% of All Funds
0.22%
New
35
Increased
190
Reduced
191
Closed
75
Calls
$139​M
Puts
$87.5​M
Net Calls
+$51.7​M
Net Calls Change
+$62.2​M

BMRN Hedge Fund Activity: Q3 2023 in Review

518 of the 6,315 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2023, worth a combined $16.1B — up 3.6% from $15.5B a quarter earlier.

Sellers outnumbered buyers: 75 funds closed out of BMRN and 35 opened new positions — a net loss of 40 holders — while 191 trimmed existing stakes and 190 added.

The largest buyer was Barclays, adding an estimated $259M. The largest seller was Bank of America, cutting an estimated $113M.

  • 518 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2023, down from 555 in Q2 2023.
  • Funds reported $16.1B of BioMarin Pharmaceuticals stock for Q3 2023, up 3.6% quarter-over-quarter.
  • 35 funds opened new BioMarin Pharmaceuticals positions in Q3 2023 and 75 closed out, a net change of -40 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q3 2023 was Barclays, an estimated $259M added.
  • The largest BioMarin Pharmaceuticals seller in Q3 2023 was Bank of America, an estimated $113M sold.

Based on aggregated 13F filings for Q3 2023.